The market for STI testing is large because a lot of routine screening goes on in the area and chlamydia in particular doesn't necessarily give rise to symptoms. I would say its one of the most common pathology tests and its not season dependent like influenza. So potentially the approval will boost things nicely just in the domestic market.
Ann: Update to major customer contract announcement, page-15
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
67.5¢ |
Change
-0.015(2.17%) |
Mkt cap ! $155.4M | |||
| Open | High | Low | Value | Volume |
| 68.5¢ | 68.5¢ | 67.5¢ | $8.27K | 12.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34322 | 67.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 68.5¢ | 7757 | 1 |
View Market Depth
| Last trade - 13.57pm 29/11/2024 (20 minute delay) ? |
| GSS (ASX) Chart |
